Status:
COMPLETED
Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation
Lead Sponsor:
Karolinska Institutet
Conditions:
Prostate Cancer
Prostate Cancer Screening
Eligibility:
MALE
75-79 years
Brief Summary
Opportunistic prostate-specific antigen (PSA) testing is widespread among men aged 75-79. Current American and European guidelines recommend PSA-based screening through shared decision-making if men a...
Eligibility Criteria
Inclusion
- Men aged 75-79 between 2007-2023, with no prostate cancer diagnosis at the time of inclusion (based on each trial emulation) will be considered eligible for the trials. To ensure proper control for potential confounding, and to be able to evaluate the eligibility criteria, only men with complete information on their screening status, outcomes, and confounders in the registers will be included.
Exclusion
- Men younger than 75 or older than 79 between 2007-2023. Have prostate cancer diagnosis at the time of inclusion (based on each trial emulation) Missing data on the exposure, outcomes, and confounders.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
257275 Patients enrolled
Trial Details
Trial ID
NCT07206693
Start Date
January 1 2007
End Date
December 31 2023
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stockholm, Sweden